Li ZHUANG

Li ZHUANG


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2023 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
KLKe Li
Ke Li
QGQuan Gong
Quan Gong
XXXu-Dong Xiang
Xu-Dong Xiang
GGGang Guo
Gang Guo
JLJia Liu
Jia Liu
LZLi ZHUANG
Li ZHUANG
Background: Accumulating data indicate that N6-methyladenosine (m6A) RNA methylation and lncRNA deregulation act crucial roles in cancer progression. Heterogeneous nuclear ribonucleoprotein A2B1 (HNRNPA2B1) as an m6A “reader” has been reported to be an oncogene in multiple malignancies. We herein aimed to elucidate the role and underlying mechanism by which HNRNPA2B1-mediated m6A modification of lncRNAs contributes to non-small cell lung cancer (NSCLC). Methods: The expression levels of HNRNPA2B1 and their association with the clinicopathological characteristics and prognosis in NSCLC were determined by RT-qPCR, Western blot, immunohistochemistry and TCGA dataset. Then, the role of HNRNPA2B1 in NSCLC cells was assessed by in vitro functional experiments and in vivo tumorigenesis and lung metastasis models. HNRNPA2B1-mediated m6A modification of lncRNAs was screened by m6A-lncRNA epi-transcriptomic microarray and verified by methylated RNA immunoprecipitation (Me-RIP). The lncRNA MEG3-specific binding with miR-21-5p was evaluated by luciferase gene report and RIP assays. The effects of HNRNPA2B1 and (or) lncRNA MEG3 on miR-21-5p/PTEN/PI3K/AKT signaling were examined by RT-qPCR and Western blot analyses. Results: We found that upregulation of HNRNPA2B1 was associated with distant metastasis and poor survival, representing an independent prognostic factor in patients with NSCLC. Knockdown of HNRNPA2B1 impaired cell proliferation and metastasis in vitro and in vivo, whereas ectopic expression of HNRNPA2B1 possessed the opposite effects. Mechanical investigations revealed that lncRNA MEG3 was an m6A target of HNRNPA2B1 and inhibition of HNRNPA2B1 decreased MEG3 m6A levels but increased its mRNA levels. Furthermore, lncRNA MEG3 could act as a sponge of miR-21-5p to upregulate PTEN and inactivate PI3K/AKT signaling, leading to the suppression of cell proliferation and invasion. Low expression of lncRNA MEG3 or elevated expression of miR-21-5p indicated poor survival in patients with NSCLC. Conclusions: Our findings uncover that HNRNPA2B1-mediated m6A modification of lncRNA MEG3 promotes tumorigenesis and metastasis of NSCLC cells by regulating miR-21-5p/PTEN axis and may provide a therapeutic target for NSCLC.

9 March 2020 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
KLKe Li
Ke Li
YJYongxin Jiang
Yongxin Jiang
XXXudong Xiang
Xudong Xiang
QGQuan Gong
Quan Gong
CZChunyan Zhou
Chunyan Zhou
LZLi ZHUANG
Li ZHUANG
Background: The aim of this study was to determine the function of long non‐coding RNA small nucleolar RNA host gene 6 (SNHG6) in non‐small cell lung cancer (NSCLC) and its underlying mechanisms.Methods: The association of SNHG6 or miR‐101‐3p with clinicopathological characteristics and prognosis in patents with NSCLC was assessed by TCGA dataset. Cell proliferation and invasion were evaluated by MTT and Transwell assays and SNHG6‐specific binding with miR‐101‐3p was verified by bioinformatic analysis, luciferase gene report and RNA immunoprecipitation assays. qRT‐PCR and Western blot was used to assess the effects of SNHG6 on the expression of miR‐101‐3p and chromodomain Y like (CDYL) in NSCLC cells. A xenograft tumor model in vivo was established to observe the effects of SNHG6 knockdown on tumor growth.Results: We found that increased expression of SNHG6 was associated with pathological stage and lymph node infiltration, and acted as an independent prognostic factor of tumor recurrence in patients with NSCLC. Silencing SNHG6 expression repressed cell growth and invasion in vitro and in vivo, but overexpression of SNHG6 reversed these effects. Furthermore, SNHG6 was identified to act as a sponge of miR‐101‐3p, which could reduce cell proliferation and attenuate SNHG6‐induced CDYL expression. Low expression of miR‐101‐3p or high expression of CDYL was related to poor survival in patients with NSCLC.Conclusions: Our findings demonstrated that lncRNA SNHG6 contributed to the proliferation and invasion of NSCLC by downregulating miR‐101‐3p.

22 July 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
KZKunzhong Zhou
Kunzhong Zhou
YLYuewen Li
Yuewen Li
WWWeifang Wang
Weifang Wang
YCYilin Chen
Yilin Chen
BQBingyan Qian
Bingyan Qian
LZLi ZHUANG
Li ZHUANG
Therapeutic responses to identical chemotherapy regimens often vary significantly among patients with the same type of cancer, underscoring the need for additional biomarkers to identify individuals most likely to benefit from specific treatments. The expression of SLFN11 (Schlafen11) has been identified as a potential biomarker for predicting patient responses to DNA-damaging agents and PARP inhibitors, as it irreversibly blocks DNA replication under replication stress, thereby increasing the sensitivity of cancer cells to various DNA-damaging agents and PARP inhibitors. Preclinical and clinical trial data suggest that SLFN11 can predict therapeutic responses to multiple DNA- targeted drugs, including platinum-based agents, topoisomerase I/II inhibitors, DNA synthesis inhibitors, and PARP inhibitors. Leveraging the expression status of SLFN11 or modulating its expression offers exciting possibilities for clinical applications. In this review, we summarize the structure and function of SLFN11, as well as its progress as a biomarker across various cancer types. We also review the regulation of SLFN11 expression, its dynamic expression patterns, and potential strategies for combination therapies to enhance efficacy based on SLFN11 status. Furthermore, we discuss the potential of SLFN11 expression status in overcoming resistance to DNA-damaging drugs, optimizing treatment strategies, and advancing precision cancer therapy.

1 January 2021 in International Journal of Immunopathology and Pharmacology
Verified
Journal Article
Open access
PDF file
KLKe Li
Ke Li
HNHuatao Niu
Huatao Niu
YWYing Wang
Ying Wang
RLRuilei Li
Ruilei Li
YZYuan Zhao
Yuan Zhao
LZLi ZHUANG
Li ZHUANG
Introduction: Increasing evidence indicates that lncRNA TUG1 represents an oncogenic factor in cancer. But, the mechanisms by which lncRNA TUG1 contributes to lung adenocarcinoma (LAC) remain undocumented. Methods: The relationship between lncRNA TUG1/miR-138-5p expression and clinical outcomes in patients with LAC was indicated by qPCR, FISH, and TCGA cohort. Gain- or loss-of-function experiments and in vivo tumorigenesis were used to assess the role of lncRNA TUG1 in LAC. The interplay between TUG1 and miR-138-5p was validated by luciferase gene report and RIP assays. qPCR and Western blot analyses were used to investigate the effects of TUG1 on miR-138-5p/HIF1A axis in LAC cells. Results: We found that upregulation of TUG1 or downregulation of miR-138-5p was associated with lymph node or distant metastasis and indicated a poor survival in LAC. Reduced expression of TUG1 restrained the growth of LAC cells, while restored expression of TUG1 had the opposite effects. TUG1 was identified to negatively regulate miR-138-5p expression, and miR-138-5p reversed TUG1-induced cell proliferation by targeting HIF1A. Elevated expression of HIF1A predicted a poor survival in LAC. Conclusion: Our findings demonstrate that lncRNA TUG1 promotes the growth of LAC by regulating miR-138-5p-HIF1A axis.

22 June 2021 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
QGQuan Gong
Quan Gong
JDJing Deng
Jing Deng
LZLijuan Zhang
Lijuan Zhang
CZChunyan Zhou
Chunyan Zhou
CFChaojiang Fu
Chaojiang Fu
LZLi ZHUANG
Li ZHUANG
Non‑small cell lung cancer (NSCLC) is one of the most common malignancies with high rates of mortality. Although great progress has been made with the development of novel immunotherapies and targeted therapeutic strategies, the 5‑year total survival rate of lung cancer has remained unchanged over the past few decades. Therefore, more effective therapeutics are urgently needed. Tumor endothelial marker 8 (TEM8) is an integrin‑like cell surface transmembrane protein that has been demonstrated to be upregulated in numerous cancer types and previously showed promise for targeted cancer therapy. However, the role of TEM8 in NSCLC remains poorly understood. The present study aimed to investigate the effects of silencing TEM8 on expression and regulation of extracellular signal‑regulated kinase (ERK)1/2 signaling pathways in NSCLC. In the present study, a lentiviral vector that encoded a short hairpin RNA targeting TEM8 was designed and transfected into Xuanwei Lung Cancer (XWLC)‑05 lung cancer cells to silence TEM8 expression. Male BALB/c‑nu/nu mice were then given subcutaneous injections in the right dorsal flank with XWLC‑05 cells. Microvessel density was measured using an anti‑CD34 antibody. The mRNA and protein levels of ERK1/2 and Bcl‑2 in XWLC‑05 cells or xenograft tumor tissues were detected by reverse transcription‑quantitative polymerase chain reaction and western blotting. TEM8 knockdown was found to significantly inhibit tumor growth and conferred an anti‑angiogenic ability in vivo. Furthermore, TEM8 knockdown suppressed the expression of Bcl‑2 mediated by ERK1/2 activity in XWLC‑05 cells or tissues from mice with NSCLC. To conclude, these results suggest that the targeted silencing of TEM8 may serve as an effective method of treating NSCLC.

4 February 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
KZKunzhong Zhou
Kunzhong Zhou
YLYuewen Li
Yuewen Li
WWWeifang Wang
Weifang Wang
YCYilin Chen
Yilin Chen
BQBingyan Qian
Bingyan Qian
LZLi ZHUANG
Li ZHUANG